Generic Name: insulin degludec + liraglutide
Brand Name: Xultophy
Manufacturer: Novo Nordisk Canada Inc.
Indications: Diabetes mellitus, Type 2
Manufacturer Requested Reimbursement Criteria1:
To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control.
Submission Type: New Combination
Project Status: Pending
Call For Patient Input: January 2, 2019
Patient Input Closed: February 21, 2019
Anticipated Date: January 30, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.